How does pre-transplant MRD affect outcome in AML?

During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How does pre-transplant measurable residual disease (MRD) affect outcome in AML?

In this video, Nagler discusses how pre-transplant MRD, the most important predictive factor, affects the outcome of transplantation in AML. Patients who are MRD-negative pre-transplant have a lower relapse rate, and better leukemia-free and overall survival; however, MRD does not appear to affect transplant-related mortality. Nagler goes on to describe the results of a study investigating whether MRD dictates transplant results in patients that received post-transplant cyclosporine as graft-versus-host disease prophylaxis.